Avilar Therapeutics

Avilar Therapeutics is a biopharmaceutical company based in Waltham, MA, specializing in the pioneering the discovery and development of extracellular protein degraders. Founded in 2020, the company has recently received a $15.00M Seed Round investment on 16 February 2023 from notable investors including RA Capital Management, Astellas Venture Management, Medical Excellence Capital, and Sanofi Ventures. Avilar's focus lies in developing ATACs (ASGPR Targeting Chimeras), a novel class of protein degrader therapeutics designed to shuttle disease-causing proteins from circulation to the endolysosome for degradation. The company's proprietary ATAC platform includes high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation, allowing for the modular design and synthesis of ATACs extendable across the extracellular proteome. With a mission to address a wide range of proteins involved in the pathogenesis of human diseases, Avilar Therapeutics is leveraging their ATAC platform to build a diverse pipeline of first-in-class extracellular protein degraders. With strong financial backing and a pioneering approach, Avilar is poised to make significant contributions to the biotechnology and pharmaceutical industries.